Detalles de la búsqueda
1.
Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice.
Mult Scler
; 29(2): 196-205, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36377744
2.
Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP).
Mult Scler
; 27(3): 410-419, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32406786
3.
Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program.
Mult Scler
; 27(5): 719-728, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32579430
4.
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
J Neurol Neurosurg Psychiatry
; 91(6): 660-668, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32234967
5.
Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies.
Ther Adv Neurol Disord
; 17: 17562864231221331, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38414723
6.
Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world.
Expert Opin Drug Saf
; 22(10): 995-1002, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37272350
7.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Lancet Neurol
; 21(7): 608-619, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35483387
8.
Chronic lesion activity and disability progression in secondary progressive multiple sclerosis.
BMJ Neurol Open
; 4(1): e000240, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35720980
9.
No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
Mult Scler Relat Disord
; 58: 103480, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35051898
10.
Endogenous signaling through alpha7-containing nicotinic receptors promotes maturation and integration of adult-born neurons in the hippocampus.
J Neurosci
; 30(26): 8734-44, 2010 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-20592195
11.
Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing.
J Clin Pharmacol
; 61(3): 339-348, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32949472
12.
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP).
Ther Adv Neurol Disord
; 14: 17562864211042458, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34603507
13.
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study.
BMJ Open
; 10(10): e038861, 2020 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33082194
14.
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
Neurology
; 93(15): e1452-e1462, 2019 10 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31515290
15.
Extended-interval dosing of natalizumab in NOVA - Authors' reply.
Lancet Neurol
; 22(3): 200-201, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36804085
16.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Lancet Neurol
; 17(5): 405-415, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29545067
17.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Lancet Neurol
; 16(11): 925-933, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28969984
18.
The risk of PML from natalizumab - Authors' reply.
Lancet Neurol
; 18(3): 230-231, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30784549
19.
Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.
Mult Scler Relat Disord
; 3(6): 705-11, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25891549
20.
Imaging neural activity using Thy1-GCaMP transgenic mice.
Neuron
; 76(2): 297-308, 2012 Oct 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-23083733